Benjamin Landry Sells 13,827 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the sale, the general counsel now owns 160,437 shares of the company’s stock, valued at approximately $729,988.35. This represents a 7.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Benjamin Landry also recently made the following trade(s):

• On Monday, January 6th, Benjamin Landry sold 2,500 shares of Health Catalyst stock. The stock was sold at an average price of $7.52, for a total transaction of $18,800.00.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $4.43 on Thursday. Health Catalyst, Inc. has a fifty-two week low of $3.76 and a fifty-two week high of $9.24. The company has a 50 day simple moving average of $5.56 and a two-hundred day simple moving average of $7.10. The company has a market capitalization of $311.03 million, a price-to-earnings ratio of -3.28 and a beta of 1.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently made changes to their positions in HCAT. Creative Planning increased its stake in shares of Health Catalyst by 13.2% during the third quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after purchasing an additional 2,486 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Health Catalyst during the third quarter valued at approximately $897,000. Impax Asset Management Group plc increased its stake in shares of Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after purchasing an additional 360,201 shares in the last quarter. Summit Global Investments increased its stake in shares of Health Catalyst by 8.1% during the third quarter. Summit Global Investments now owns 66,544 shares of the company’s stock valued at $542,000 after purchasing an additional 4,991 shares in the last quarter. Finally, Quest Partners LLC bought a new position in shares of Health Catalyst during the third quarter valued at approximately $34,000. Institutional investors own 85.00% of the company’s stock.

Analyst Ratings Changes

HCAT has been the subject of a number of analyst reports. Piper Sandler dropped their target price on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Royal Bank of Canada dropped their target price on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th. Stifel Nicolaus dropped their target price on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a report on Thursday, February 27th. Canaccord Genuity Group decreased their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 21st. Finally, KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a research note on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Health Catalyst currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.27.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.